- Home
- ETJ vs SEPN Comparison
ETJ vs SEPN Comparison
Compare ETJ & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETJ
- SEPN
- Stock Information
- Founded
- ETJ 2007
- SEPN 2022
- Country
- ETJ United States
- SEPN United States
- Employees
- ETJ N/A
- SEPN N/A
- Industry
- ETJ Finance Companies
- SEPN
- Sector
- ETJ Finance
- SEPN
- Exchange
- ETJ Nasdaq
- SEPN NYSE
- Market Cap
- ETJ 578.8M
- SEPN 631.0M
- IPO Year
- ETJ N/A
- SEPN 2024
- Fundamental
- Price
- ETJ $8.17
- SEPN $5.90
- Analyst Decision
- ETJ
- SEPN Buy
- Analyst Count
- ETJ 0
- SEPN 4
- Target Price
- ETJ N/A
- SEPN $33.00
- AVG Volume (30 Days)
- ETJ 175.6K
- SEPN 257.0K
- Earning Date
- ETJ 01-01-0001
- SEPN 05-15-2025
- Dividend Yield
- ETJ 8.30%
- SEPN N/A
- EPS Growth
- ETJ N/A
- SEPN N/A
- EPS
- ETJ N/A
- SEPN N/A
- Revenue
- ETJ N/A
- SEPN $1,075,000.00
- Revenue This Year
- ETJ N/A
- SEPN N/A
- Revenue Next Year
- ETJ N/A
- SEPN N/A
- P/E Ratio
- ETJ N/A
- SEPN N/A
- Revenue Growth
- ETJ N/A
- SEPN 611.92
- 52 Week Low
- ETJ $7.20
- SEPN $4.17
- 52 Week High
- ETJ $8.47
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- ETJ 43.06
- SEPN N/A
- Support Level
- ETJ $7.40
- SEPN N/A
- Resistance Level
- ETJ $8.87
- SEPN N/A
- Average True Range (ATR)
- ETJ 0.33
- SEPN 0.00
- MACD
- ETJ -0.00
- SEPN 0.00
- Stochastic Oscillator
- ETJ 52.38
- SEPN 0.00
About ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.